A study of the efficacy and safety of combination therapy of xelox and bevacizumab for elderly patients in over the age of 75 with advanced or recurrent colorectal cancer

今回われわれは75歳以上高齢者の進行･再発大腸癌に対してベバシズマブ+XELOX療法の効果について検討したので症例呈示も含め報告する.対象は当院でベバシズマフﾞ+XELOX療法が3コース以上施行できた75歳以上高齢者の進行･再発大腸癌患者12例とした.(75?84

We investigated the efficacy and safety of combination therapy of XELOX and Bevaci-zumab in late-stage elderly patients with advanced or recurrent colorectal cancer. We report the result including a few case presentation. 12 patients who received XELOX and Bevacizumab therapy for 3 cycle or more in our hospital were evaluated.After first treatment, the response rate in all patients was 50% and the disease control rate was 58.3%(CR:1/12, PR:5/12, NC:1/12, PD:5/12).But 6 months later, the response rate was decreased to 8.3%. 5 cases were found to be ineffective in first treatment of this regimen, so next another chemotherapy were administered to them, but 4 of 5 were found to be ineffective and followed best supportive care. On the other hand 1 of 5 was found to be partial response. 7 cases were found to be effective, but 5 of 7 were obliged to be interrupted chemotherapy due to general fatigue or anorexia, and all of 5 were found to be progressive disease in 6 months later of first treatment. In over the age of 80, the response rate was 42.3%(3/7),the desease control rate was 42.3%(3/7).Bevacizumab and XELOX therapy was effective in elderly patients with advanced or recurrent colorectal cancer. It is very important to manage the side effects for continuity of chemotherapy.

高齢者大腸癌

ベバシズマブ+XELOX療法

進行･再発大腸癌